Europe
GBA Group Pharma has informed its industry partners and clients on risks to their clinical trial plans caused by Brexit and is highlighting the significant business difficulties for healthcare companies running clinical trials through UK-based organisations.
Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
The focus is on containment, although a number of organizations and companies are beginning work on vaccines.
Abcam’s new CRISPR-Cas9 knockout cell lines provide reproducible, single gene KOs that support the interrogation of the relationship between genotype and phenotype.
International research team published initial clinical trial results in Nature Medicine of nine X-Linked Chronic Granulomatous Disease (CGD) patients
Forbion, a leading European life sciences venture capital firm, announces that Dr. John Montana has joined Forbion as Operating Partner, effective 1st January 2020.
It was another busy week for clinical trial updates. Here’s a look.
Three months after Sandoz announced it would acquire the Japanese business of Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings for $330 million, the deal has been completed.
The new data should give Bayer’s Nubeqa some energy to go after market share held by other drugs approved to treat prostate cancer, including Xtandi.
Latest approval for apalutamide could benefit a population of more than 100,000 people living with mHSPC across Europe.
PRESS RELEASES